Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback
US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared…
US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared…
Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting all…
The World Health Organization (WHO) has released a series of papers in The Lancet detailing the work that needs to…
Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one…
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move…
The biotech and biopharma industry has struggled in recent years with a lack of investment. While GlobalData has tracked an…
There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases…
MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study…
It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst…